| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5855906 | MILLICENT | Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors |
Dec, 2015
(8 years ago) | |
Femring is owned by Millicent.
Femring contains Estradiol Acetate.
Femring has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Femring are:
- US5855906
Femring was authorised for market use on 20 March, 2003.
Femring is available in insert, extended release;vaginal dosage forms.
Femring can be used as method of releasing 17-beta oestradiol precursor in a substantially zero order pattern for at least three weeks.
The generics of Femring are possible to be released after 19 December, 2015.
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 March, 2003
Treatment: Method of releasing 17-beta oestradiol precursor in a substantially zero order pattern for at least three weeks
Dosage: INSERT, EXTENDED RELEASE;VAGINAL
FEMRING family patents
